查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951260

淋巴水腫診斷市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、疾病、最終用戶、地區和競爭格局分類，2021-2031年）

Lymphedema Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Disease, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球淋巴水腫診斷市場預計將從 2025 年的 4,356 萬美元成長到 2031 年的 6,835 萬美元，複合年成長率為 7.80%。

此細分市場包括電阻阻抗譜和淋巴閃爍顯像等醫學影像技術和篩檢設備，用於識別淋巴系統功能障礙並測量患者的體液儲存。推動市場擴張的關鍵因素包括癌症倖存者次發性淋巴水腫在全球的盛行率不斷上升，以及人口老化導致慢性靜脈功能不全的易感性增加。這些結構性因素使得人們持續需要可靠的檢測設備，以便在病情惡化前進行管理。根據淋巴教育與研究網路 (LERN) 2024 年發布的數據，淋巴水腫影響著美國約 1,000 萬人和全球超過 2.5 億人，凸顯了開發精準診斷工具以支持早期治療和改善患者預後的緊迫性。

市場概覽
預測期 2027-2031
市場規模：2025年 4356萬美元
市場規模：2031年 6835萬美元
複合年成長率：2026-2031年 7.8%
成長最快的細分市場 淋巴閃爍顯像
最大的市場 北美洲

全球淋巴水腫診斷市場擴張的主要障礙在於先進影像設備的高成本以及許多地區保險覆蓋不足。缺乏專業淋巴評估的報銷往往阻礙了醫療專業人員採用最新技術，並限制了患者獲得重要診斷服務的機會。這種經濟障礙在開發中國家的醫療資金有限，資源分配往往優先考慮急性病治療而非慢性病管理。

市場促進因素

癌症相關次發性淋巴水腫盛行率的上升是診斷市場的主要驅動力，尤其是在全球乳癌和骨盆腔癌存活率持續提高的情況下。醫療機構越來越重視對癌症倖存者進行早期淋巴功能障礙的舉措，因此需要頻繁應用淋巴閃爍造影和電阻譜等診斷工具。由於次發性淋巴水腫是一種慢性疾病，通常在治療後數月至數年內出現，癌症倖存者人數的不斷成長導致對持續後續觀察的需求持續增加。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》，預計2024年美國女性將新增約310,720例侵襲性乳癌病例。患者數量的增加直接轉化為對精準檢測設備需求的成長，因為這些患者面臨終身慢性腫脹和併發症的風險，而這些併發症需要即時治療。

非侵入性診斷方法的技術進步，透過實現更精準、以患者為中心的評估，進一步推動了市場成長。製造商正在將診斷設備與數位健康生態系統整合，以最佳化數據收集，這提高了淋巴水腫和血管疾病專科診所的採用率。這種現代化趨勢也體現在主要產業參與者的財務表現中，他們正在擴展產品系列以滿足臨床需求。例如，Tactile Systems Technology, Inc. 在其於 2024 年 2 月發布的「2023 會計年度第四季度及全年財務業績」中報告稱，其全年總收入達到 2.744 億美元，這主要得益於對淋巴水腫管理和診斷解決方案的強勁需求。此外，全球癌症負擔持續加重，需要可擴展的診斷基礎設施來應對未來不斷成長的病例量。 2024 年，國際癌症研究機構 (IARC) 預測癌症治療需求將出現大規模激增，估計到 2050 年，每年將新增 3500 多萬例癌症病例，這凸顯了長期需要強大的淋巴水腫診斷能力。

市場挑戰

高階診斷影像系統高昂的成本以及保險覆蓋不足是阻礙因素。由於報銷的不確定性和投資報酬率低，醫療機構往往不願意投資昂貴的設備，例如淋巴閃爍顯像儀和電阻譜儀。在許多地區，支付方將專業的淋巴影像歸類為非必要或研究性檢查，導致理賠被拒，限制了其臨床應用。這種資金支持的匱乏迫使醫療服務提供者依賴主觀的身體檢查而非精準的設備診斷，導致設備製造商的收入成長停滯不前。

此外，沉重的經濟負擔也成為患者接受這些診斷程序的一大障礙。根據美國整形外科醫師協會統計，到2025年，保守性淋巴水腫治療的平均費用為每位患者14,648美元，其中平均自付費用為9,765美元。如此高昂的自付費用阻礙了患者接受全面的診斷評估，並迫使醫療系統優先考慮急性治療而非慢性病管理手段。因此，在醫療服務提供者和患者都面臨不利的經濟環境下，市場對先進篩檢技術的需求正在下降。

市場趨勢

攜帶式、可攜式照護現場設備的出現，透過分散肢體體積測量，從根本上改變了診斷格局。臨床醫生正逐漸摒棄笨重昂貴的周徑儀，轉而擴大採用基於行動應用程式的3D成像解決方案，這些方案可在標準智慧型手機上提供臨床等級的精確度。這種技術的普及滿足了非專業、資源匱乏地區對便利篩檢的迫切需求，使早期療育無需大量資金投入。根據Docwire News（2025年3月）發表的報導「應用程式成功檢測乳癌患者的淋巴水腫」的文章報道，LymphaTech 3D影像系統近期的一項檢驗表明，與傳統週徑儀方法相比，其組內相關係數（ICC）大於0.99，證實了其在廣泛臨床應用中的可靠性。

同時，用於遠端患者監護的數位健康平台的擴展，正在為慢性病管理建立一個更整合、更協作的醫療環境。業界領先企業正轉向下一代互聯設備，這些設備能夠無縫整合治療方案數位資料追蹤，從而提高患者依從性並長期監測疾病進展。這種策略整合正在推動強勁的商業性應用，因為醫療服務提供者優先考慮能夠簡化患者數據的生態系統。根據Tactile Systems Technology在2025年11月舉行的“2025年第三季度財報電話會議”，其淋巴水腫治療產品的收入達到7240萬美元，同比成長11%，這主要得益於該公司互聯平台Nimbl的普及和廣泛應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球淋巴水腫診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過技術（電阻分析、電腦斷層掃描、淋巴閃爍顯像、磁振造影、近紅外線螢光成像、超音波成像、X光造影）
    • 依疾病分類（癌症、心血管疾病、發炎性疾病）
    • 按最終使用者（診斷中心、醫院、研究和學術機構等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美淋巴水腫診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲淋巴水腫診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區淋巴水腫診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲淋巴水腫診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲淋巴水腫診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球淋巴水腫診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • ImpediMed
  • BioCompression Systems
  • Mego Afek
  • Stryker
  • Philips Healthcare
  • GE HealthCare
  • Siemens Healthineers
  • Canon Medical
  • Perimed
  • Fluoptics

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20645

The Global Lymphedema Diagnostics Market is projected to increase from a valuation of USD 43.56 Million in 2025 to USD 68.35 Million by 2031, expanding at a CAGR of 7.80%. This market sector encompasses medical imaging technologies and screening apparatuses, such as bioimpedance spectroscopy and lymphoscintigraphy, which are employed to identify lymphatic system dysfunction and measure fluid accumulation in patients. Key drivers fueling market expansion include the growing worldwide prevalence of secondary lymphedema among cancer survivors and an aging demographic susceptible to chronic venous insufficiency. These structural factors generate a continuous need for reliable detection instruments to manage the condition prior to its progression. As stated by the Lymphatic Education & Research Network in 2024, lymphedema affects approximately 10 million individuals in the United States and over 250 million globally, highlighting the urgent requirement for precise diagnostic tools to support early treatment and enhanced patient outcomes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 43.56 Million
Market Size 2031USD 68.35 Million
CAGR 2026-20317.8%
Fastest Growing SegmentLymphoscintigraphy
Largest MarketNorth America

A major obstacle limiting the broader development of the Global Lymphedema Diagnostics Market is the high expense associated with sophisticated imaging machinery and the insufficiency of insurance coverage in numerous regions. The scarcity of reimbursement frameworks for specialized lymphatic assessments frequently deters medical practitioners from implementing modern technologies and restricts patient entry to critical diagnostic services. This economic hurdle is especially damaging in developing nations where healthcare funding is restricted, and resource distribution frequently favors acute medical care over systems designed for managing chronic diseases.

Market Driver

The rising prevalence of cancer-associated secondary lymphedema serves as a primary catalyst for the diagnostics market, especially as global survival rates for breast and pelvic cancers continue to improve. Healthcare providers are increasingly emphasizing surveillance initiatives to detect early-stage lymphatic dysfunction in survivors, necessitating the frequent application of diagnostic tools such as lymphoscintigraphy and bioimpedance spectroscopy. Because secondary lymphedema is a chronic condition that often manifests months or years post-treatment, the expanding population of cancer survivors generates a lasting demand for longitudinal monitoring. Data from the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, indicates that approximately 310,720 new invasive breast cancer cases were expected to be diagnosed in women in the United States that year. This increasing patient volume directly translates to a heightened need for accurate detection devices, as these individuals face a lifelong risk of chronic swelling and associated complications requiring immediate care.

Technological advancements in non-invasive diagnostic modalities are further driving market growth by facilitating more precise and patient-centric assessments. Manufacturers are integrating digital health ecosystems with diagnostic hardware to optimize data collection, thereby fostering higher adoption rates among clinics specialized in lymphedema and vascular disorders. This modernization is evident in the financial results of key industry players who are broadening their portfolios to address clinical needs. For instance, Tactile Systems Technology reported in their 'Fourth Quarter and Fiscal Year 2023 Financial Results' in February 2024 that the company achieved a total annual revenue of $274.4 million, fueled by strong demand for their lymphedema management and diagnostic solutions. Moreover, the global burden of cancer continues to require scalable diagnostic infrastructure to handle future caseloads; the International Agency for Research on Cancer predicted in 2024 a widespread surge in oncology needs, estimating over 35 million new cancer cases annually by 2050, which reinforces the long-term requirement for robust lymphedema diagnostic capabilities.

Market Challenge

The significant expense associated with high-end imaging systems and the absence of adequate insurance coverage act as major restraints on the expansion of the Global Lymphedema Diagnostics Market. Healthcare facilities often hesitate to invest in costly capital equipment, such as lymphoscintigraphy units or bioimpedance spectroscopy devices, due to the uncertainty of reimbursement and low return on investment. In many jurisdictions, payers classify specialized lymphatic imaging as non-essential or investigational, resulting in denied claims and restricted clinical adoption. This lack of financial support compels medical providers to rely on subjective physical examinations rather than precise instrumental diagnostics, thereby stalling the revenue growth of device manufacturers.

Moreover, the heavy financial liability placed on patients creates a significant barrier to accessing these diagnostic procedures. According to the American Association of Plastic Surgeons, in 2025, the average cost for conservative lymphedema management was $14,648 per patient, with average out-of-pocket expenses reaching $9,765. This high level of personal financial burden discourages patients from pursuing comprehensive diagnostic evaluations and compels healthcare systems to prioritize acute care spending over chronic management tools. Consequently, the market faces reduced demand for sophisticated screening technologies as the economic ecosystem remains unfavorable for both providers and patients.

Market Trends

The emergence of handheld and portable point-of-care devices is fundamentally reshaping the diagnostic landscape by decentralizing limb volume measurement. Clinicians are increasingly moving away from bulky, expensive perometers in favor of mobile application-based 3D imaging solutions that offer clinical-grade accuracy on standard smartphones. This technological democratization addresses the critical need for accessible screening in non-specialized and resource-limited settings, allowing for earlier intervention without heavy capital investment. According to Docwire News, March 2025, in the 'App Successfully Detects Lymphedema in Breast Cancer Patients' article, a recent validation of the LymphaTech 3D Imaging System demonstrated intraclass correlation coefficients of >=0.99 when compared to traditional perometer methods, confirming its reliability for widespread clinical utility.

Simultaneously, the expansion of digital health platforms for remote patient monitoring is fostering a more integrated and connected care environment for chronic management. Industry leaders are pivoting towards next-generation connected devices that seamlessly combine therapeutic delivery with digital data tracking, thereby enhancing patient compliance and enabling longitudinal surveillance of disease progression. This strategic integration is driving robust commercial adoption as healthcare providers prioritize ecosystems that streamline patient data. According to Tactile Systems Technology, November 2025, in the 'Q3 2025 Earnings Call Transcript', the company reported that lymphedema product revenue increased 11% year-over-year to $72.4 million, significantly driven by the market introduction and uptake of their connected Nimbl platform.

Key Market Players

  • ImpediMed
  • BioCompression Systems
  • Mego Afek
  • Stryker
  • Philips Healthcare
  • GE HealthCare
  • Siemens Healthineers
  • Canon Medical
  • Perimed
  • Fluoptics

Report Scope

In this report, the Global Lymphedema Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lymphedema Diagnostics Market, By Technology

  • Bioimpedance Analysis
  • Computed Tomography
  • Lymphoscintigraphy
  • Magnetic Resonance Imaging
  • Near-Infrared Fluorescence Imaging
  • Ultrasound Imaging
  • X-Ray Lymphography

Lymphedema Diagnostics Market, By Disease

  • Cancer
  • Cardiovascular Disease
  • Inflammatory Diseases

Lymphedema Diagnostics Market, By End User

  • Diagnostic Centers
  • Hospitals
  • Research & Academic Institutes
  • Others

Lymphedema Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lymphedema Diagnostics Market.

Available Customizations:

Global Lymphedema Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lymphedema Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography)
    • 5.2.2. By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases)
    • 5.2.3. By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Lymphedema Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Disease
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lymphedema Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Lymphedema Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Lymphedema Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By End User

7. Europe Lymphedema Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Disease
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lymphedema Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By End User
    • 7.3.2. France Lymphedema Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Lymphedema Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Lymphedema Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Lymphedema Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By End User

8. Asia Pacific Lymphedema Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Disease
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Lymphedema Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By End User
    • 8.3.2. India Lymphedema Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Lymphedema Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Lymphedema Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Lymphedema Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By End User

9. Middle East & Africa Lymphedema Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Disease
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Lymphedema Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Lymphedema Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Lymphedema Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By End User

10. South America Lymphedema Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Disease
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lymphedema Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Lymphedema Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Lymphedema Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Lymphedema Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ImpediMed
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BioCompression Systems
  • 15.3. Mego Afek
  • 15.4. Stryker
  • 15.5. Philips Healthcare
  • 15.6. GE HealthCare
  • 15.7. Siemens Healthineers
  • 15.8. Canon Medical
  • 15.9. Perimed
  • 15.10. Fluoptics

16. Strategic Recommendations

17. About Us & Disclaimer